Lipoxin A4 Stabilizes Vulnerable Atherosclerotic Plaques
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for atherosclerosis primarily focus on lowering cholesterol levels and surgical procedures, lacking effective agents to stabilize vulnerable atherosclerotic plaques, which are prone to rupture and cause life-threatening conditions.
Innovation Solution
The use of lipoxin A4 (LXA4), resolvins, and their analogs to stabilize atherosclerotic plaques, administered through various formulations such as mouth rinses, chewing gum, or nanoparticles, to increase plaque stability and prevent arterial disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (statins and surgical procedures) are used to manage atherosclerosis, then cholesterol levels are lowered or arterial blockages are treated, but vulnerable plaques remain unstable and prone to rupture
Solution Approach 1:
The patent applies parameter changes by administering lipoxin A4 and resolvins to alter the biochemical composition and structural properties of the fibrous cap, transforming vulnerable plaques into stable plaques through modification of plaque morphology and composition parameters
Solution Approach 2:
The patent uses lipoxin A4 and resolvins as intermediary substances that mediate the transformation from vulnerable to stable plaques by promoting fibrous cap thickening and reducing inflammatory cell infiltration, acting as biochemical mediators between the treatment and the plaque stabilization outcome
2Stability of the object's composition
If pro-inflammatory pathways are active in vulnerable plaques, then inflammation drives plaque development, but this same inflammation makes plaques more susceptible to rupture
Solution Approach 1:
The patent converts the harmful inflammatory process into a beneficial outcome by using lipoxin A4 and resolvins to resolve inflammation, transform macrophages into foam cells, and promote fibrous cap formation, thereby converting the inflammatory damage into plaque stabilization and vulnerability reduction
Data Source
AI summary
The invention provides methods for increasing plaque stabilization using LXA4, Resolvin E1, or analog thereof. Methods are also provided for treating or preventing arterial disorders that would benefit from increased plaque stabilization using LXA4, Resolvin E1, or analog thereof.